Robert Blelloch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robert Blelloch has a total of 443 co-authors. Here are the top co-authors by number of shared publications:
- James R. Byrnes
Department of Pharmaceutical Chemistry, University of California, San Francisco
24 shared publications - Lisa L. Kirkemo
Department of Pharmaceutical Chemistry, University of California San Francisco
24 shared publications - James A. Wells
University of California, San Francisco
23 shared publications - Jiuling Yang
Department of Internal Medicine, Division of Hematology/Oncology
23 shared publications - Cassandra D. Belair
Department of Urology, University of California San Francisco, San Francisco, California
22 shared publications - Hannah Driks
Department of Urology, University of California San Francisco, San Francisco, California
21 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (10) , 1625-1642.e10
Engineered human iPSC-derived dendritic cells dressed with tumor MHC complexes as a cancer vaccine
- 25 August 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (10) , 1625-1642.e10
Open AccessEngineered human iPSC-derived dendritic cells dressed with tumor MHC complexes as a cancer vaccine
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S5: Combined loss of PVRL2 and PVR loss does not further inhibit tumor growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S5: Combined loss of PVRL2 and PVR loss does not further inhibit tumor growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S1: Proteomic analysis identifies PVRL2 on tumor-derived exosomes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S1: Proteomic analysis identifies PVRL2 on tumor-derived exosomes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S3: PVRL2 regulates CD8 T cell and NK cell activation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S3: PVRL2 regulates CD8 T cell and NK cell activation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S2: PVRL2 promotes tumor growth through an immune-dependent mechanism.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S2: PVRL2 promotes tumor growth through an immune-dependent mechanism.
- Top Cited PapersOpen Access
- 8 April 2026
- Published by Springer Nature in Nature
- Vol. 653 (8113) , 167-179
Single-cell spatiotemporal dissection of the human maternal–fetal interface
The human maternal–fetal interface is characterized by mosaic intermingling of maternal and fetal cells 1 . Yet the underlying cellular, molecular and spatial programmes remain incompletely defined. Here we generate a comprehensive atlas of the human maternal–fetal interface across normal pregnancies from early gestation to term by integrating large-scale paired single-nucleus transcriptomic and chromatin accessibility profiling with submicrometre-resolution spatial transcriptomics and CODEX multiplex protein imaging 2 , substantially boosting the spatiotemporal resolution of prior research 3 . This framework delineates common and transient cell types, states and spatial niches across the fetal and maternal compartments, reconstructs transcriptional programmes that guide cytotrophoblast and decidual stromal cell differentiation, and resolves recurrent architecture structural units that build this interface. We identify previously unrecognized arterial endothelial state transitions during cytotrophoblast-mediated spiral artery remodelling and develop a machine learning model that predicts cytotrophoblast invasiveness from transcriptomic signatures. We further discover a decidual stromal cell subtype that suppresses cytotrophoblast invasion via endocannabinoid signalling at the human maternal–fetal interface. By integrating the atlas with genome-wide association data, we pinpoint maternal and fetal cells that are most vulnerable to pre-eclampsia, preterm birth or miscarriage. This resource provides a comprehensive spatially resolved single-cell multiomic reference of the human placenta and decidua and offers a framework for decoding their normal and disordered development.
- 8 April 2026
- Published by Springer Nature in Nature
- Vol. 653 (8113) , 167-179
Top Cited PapersOpen AccessSingle-cell spatiotemporal dissection of the human maternal–fetal interface
The human maternal–fetal interface is characterized by mosaic intermingling of maternal and fetal cells 1 . Yet the underlying cellular, molecular and spatial programmes remain incompletely defined. Here we generate a comprehensive atlas of the human maternal–fetal interface across normal pregnancies from early gestation to term by integrating large-scale paired single-nucleus transcriptomic and chromatin accessibility profiling with submicrometre-resolution spatial transcriptomics and CODEX multiplex protein imaging 2 , substantially boosting the spatiotemporal resolution of prior research 3 . This framework delineates common and transient cell types, states and spatial niches across the fetal and maternal compartments, reconstructs transcriptional programmes that guide cytotrophoblast and decidual stromal cell differentiation, and resolves recurrent architecture structural units that build this interface. We identify previously unrecognized arterial endothelial state transitions during cytotrophoblast-mediated spiral artery remodelling and develop a machine learning model that predicts cytotrophoblast invasiveness from transcriptomic signatures. We further discover a decidual stromal cell subtype that suppresses cytotrophoblast invasion via endocannabinoid signalling at the human maternal–fetal interface. By integrating the atlas with genome-wide association data, we pinpoint maternal and fetal cells that are most vulnerable to pre-eclampsia, preterm birth or miscarriage. This resource provides a comprehensive spatially resolved single-cell multiomic reference of the human placenta and decidua and offers a framework for decoding their normal and disordered development.
- Open Access
KMT2C and KMT2D amplify GRHL2-driven enhancer activation
The activation of cis-regulatory enhancers is essential for cell fate specification by driving cell type-specific gene expression. Differentiation models are widely used to study enhancer biology but the asynchronous and interdependent nature of gene regulatory changes during cell state transitions can complicate mechanistic studies. To overcome these limitations, here we develop a tamoxifen-gated system for acute enhancer activation in embryonic stem cells (ESCs) based on GRHL2, a pioneer transcription factor which naturally becomes expressed as naive ESCs differentiate into the formative ESC state. Using this system, we investigate the functional relationship between GRHL2 and the histone mono-methyltransferases KMT2C and KMT2D (KMT2C/D). GRHL2 readily binds its target sites independent of KMT2C/D. However, in the absence of KMT2C/D, there are dramatic reductions in H3K4me1/2, P300 recruitment, and H3K27ac deposition at these sites as well as diminished transcriptional activation. Still, strikingly, a basal level of active enhancer mark acquisition and transcriptional activation occurs. Consistent with these findings, during the naive to formative ESC differentiation, GRHL2 enhancer remodeling and target expression is also strongly but incompletely dependent on KMT2C/D. Together, these results define a functional co-activator relationship in which KMT2C/D act as important amplifiers of GRHL2-driven enhancer activation in ESCs and establish a rapid inducible system for dissecting the kinetics and enzymatic dependencies of pioneer transcription factor mediated enhancer remodeling.
Open AccessKMT2C and KMT2D amplify GRHL2-driven enhancer activation
The activation of cis-regulatory enhancers is essential for cell fate specification by driving cell type-specific gene expression. Differentiation models are widely used to study enhancer biology but the asynchronous and interdependent nature of gene regulatory changes during cell state transitions can complicate mechanistic studies. To overcome these limitations, here we develop a tamoxifen-gated system for acute enhancer activation in embryonic stem cells (ESCs) based on GRHL2, a pioneer transcription factor which naturally becomes expressed as naive ESCs differentiate into the formative ESC state. Using this system, we investigate the functional relationship between GRHL2 and the histone mono-methyltransferases KMT2C and KMT2D (KMT2C/D). GRHL2 readily binds its target sites independent of KMT2C/D. However, in the absence of KMT2C/D, there are dramatic reductions in H3K4me1/2, P300 recruitment, and H3K27ac deposition at these sites as well as diminished transcriptional activation. Still, strikingly, a basal level of active enhancer mark acquisition and transcriptional activation occurs. Consistent with these findings, during the naive to formative ESC differentiation, GRHL2 enhancer remodeling and target expression is also strongly but incompletely dependent on KMT2C/D. Together, these results define a functional co-activator relationship in which KMT2C/D act as important amplifiers of GRHL2-driven enhancer activation in ESCs and establish a rapid inducible system for dissecting the kinetics and enzymatic dependencies of pioneer transcription factor mediated enhancer remodeling.
- Top Cited Papers
- 5 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6785) , eadt4221
Synergy between regulatory elements can render cohesin dispensable for distal enhancer function
Enhancers are critical genetic elements controlling transcription from promoters, yet how they convey regulatory information across large genomic distances remains unclear. In this study, we engineered pluripotent stem cells in which cohesin loop extrusion can be inducibly disrupted without confounding cell cycle defects. Transcriptional dysregulation is cell type specific, and not all loci with distal enhancers depend equally on cohesin extrusion. Using comparative genome editing, we demonstrated that enhancer-promoter communication over just 20 kb can require cohesin. However, promoter-proximal elements can support long-range, cohesin-independent enhancer action—even across strong CCCTC-binding factor (CTCF) insulators. Lastly, transcriptional dynamics and the emergence of embryonic cell types remain largely robust despite disrupted extrusion. Beyond establishing strategies to study cohesin in enhancer biology, our work provides mechanistic insight into cell type specificity and genomic context specificity.
- 5 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6785) , eadt4221
Top Cited PapersSynergy between regulatory elements can render cohesin dispensable for distal enhancer function
Enhancers are critical genetic elements controlling transcription from promoters, yet how they convey regulatory information across large genomic distances remains unclear. In this study, we engineered pluripotent stem cells in which cohesin loop extrusion can be inducibly disrupted without confounding cell cycle defects. Transcriptional dysregulation is cell type specific, and not all loci with distal enhancers depend equally on cohesin extrusion. Using comparative genome editing, we demonstrated that enhancer-promoter communication over just 20 kb can require cohesin. However, promoter-proximal elements can support long-range, cohesin-independent enhancer action—even across strong CCCTC-binding factor (CTCF) insulators. Lastly, transcriptional dynamics and the emergence of embryonic cell types remain largely robust despite disrupted extrusion. Beyond establishing strategies to study cohesin in enhancer biology, our work provides mechanistic insight into cell type specificity and genomic context specificity.